Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
Search for:
Insulin9623 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A28478 | 12749246 | Hepatogastroenterology | Insulin resistance in patients with steatohepatitis. | 2003 | Details |
| A28479 | 12739988 | Expert Opin Pharmacother | Current best treatment for non-alcoholic fatty liver disease. | 2003 | Details |
| A28480 | 12734049 | Curr Gastroenterol Rep | Nonalcoholic steatohepatitis in children. | 2003 | Details |
| A28485 | 12677986 | Ugeskr Laeger | [Nonalcoholic steatohepatitis. Three case reports]. | 2003 | Details |
| A28486 | 12677985 | Ugeskr Laeger | [Nonalcoholic steatohepatitis--a "new" hepatic disease]. | 2003 | Details |
| A28487 | 12668987 | Hepatology | Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. | 2003 | Details |
| A28489 | 12643175 | Curr Diab Rep | Hepatic steatosis and type 2 diabetes mellitus. | 2002 | Details |
| A28493 | 12542595 | J Gastroenterol Hepatol | Non-alcoholic steatohepatitis: what is it, and why is it important in the Asia-Pacific region? | 2003 | Details |
| A28494 | 12540784 | Hepatology | Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. | 2003 | Details |
| A28496 | 12530944 | Curr Gastroenterol Rep | Interaction of iron, insulin resistance, and nonalcoholic steatohepatitis. | 2003 | Details |
| A28497 | 12516196 | Clin Liver Dis | The liver in obesity and type 2 diabetes mellitus. | 2002 | Details |
| A28499 | 12506331 | Swiss Med Wkly | Non-alcoholic fatty liver disease: treatment options based on pathogenic considerations. | 2002 | Details |
| A28502 | 12468416 | Best Pract Res Clin Endocrinol Metab | Obesity and liver disease. | 2002 | Details |
| A28503 | 12453271 | J Gastroenterol Hepatol | Non-alcoholic fatty liver disease: an overview. | 2002 | Details |
| A28506 | 12420034 | Can J Gastroenterol | Motion - all patients with NASH need to have a liver biopsy: arguments for the motion. | 2002 | Details |
| A28508 | 12406445 | Best Pract Res Clin Gastroenterol | Other disease associations with non-alcoholic fatty liver disease (NAFLD). | 2002 | Details |
| A28510 | 12406443 | Best Pract Res Clin Gastroenterol | Steatohepatitis in children. | 2002 | Details |
| A28512 | 12406441 | Best Pract Res Clin Gastroenterol | The metabolic abnormalities associated with non-alcoholic fatty liver disease. | 2002 | Details |
| A28514 | 12406439 | Best Pract Res Clin Gastroenterol | Animal models of steatohepatitis. | 2002 | Details |
| A28515 | 12406438 | Best Pract Res Clin Gastroenterol | Pathogenesis of steatohepatitis. | 2002 | Details |
| A28518 | 12352254 | Curr Opin Pediatr | Nonalcoholic fatty liver disease (NAFLD) in children. | 2002 | Details |
| A28519 | 12296456 | Nutr Rev | Nonalcoholic fatty liver disease: pathogenesis and the role of antioxidants. | 2002 | Details |
| A28520 | 12214335 | Rev Gastroenterol Mex | [Non-alcoholic steatohepatitis]. | 2002 | Details |
| A28525 | 12122975 | Rev Gastroenterol Disord | Nonalcoholic fatty liver disease. | 2002 | Details |
| A28527 | 12077098 | Gut | Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C. | 2002 | Details |
| A28530 | 12000605 | J Gastroenterol Hepatol | Non-alcoholic fatty liver disease. | 2002 | Details |
| A28531 | 11990393 | Dig Liver Dis | Fasting insulin and uric acid levels but not indices of iron metabolism are independent predictors of non-alcoholic fatty liver disease. A case-control study. | 2002 | Details |
| A28532 | 11944631 | Semin Gastrointest Dis | Fat and the liver--a molecular overview. | 2002 | Details |
| A28534 | 22822324 | Ochsner J | Nonalcoholic Fatty liver disease from the perspective of an internist. | 2002 | Details |
| A28536 | 11910345 | Gastroenterology | Effect of iron depletion in carbohydrate-intolerant patients with clinical evidence of nonalcoholic fatty liver disease. | 2002 | Details |
| A28541 | 11768567 | Scand J Gastroenterol Suppl | Non-alcoholic steatohepatitis: clinical significance and pathogenesis. | 2001 | Details |
| A28542 | 11756758 | Adv Anat Pathol | The clinicopathologic spectrum and management of nonalcoholic fatty liver disease. | 2002 | Details |
| A28544 | 11690701 | J Hepatol | Non-alcoholic fatty liver disease in an area of southern Italy: main clinical, histological, and pathophysiological aspects. | 2001 | Details |
| A28545 | 11686402 | J Submicrosc Cytol Pathol | Lipid-rich clear-cell hepatocellular carcinoma arising in non-alcoholic steatohepatitis in a patient with diabetes mellitus. | 2002 | Details |
| A28546 | 11603045 | Tidsskr Nor Laegeforen | [Non-alcoholic steatohepatitis]. | 2001 | Details |
| A28550 | 11567710 | Lancet | Metformin in non-alcoholic steatohepatitis. | 2001 | Details |
| A28552 | 11475019 | Ned Tijdschr Geneeskd | [Abdominal obesity: metabolic complications and consequences for the liver]. | 2001 | Details |
| A28553 | 11473047 | Diabetes | Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. | 2001 | Details |
| A28555 | 11438497 | Gastroenterology | Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. | 2001 | Details |
| A28557 | 11432515 | Dig Liver Dis | Insulin resistance in non-alcoholic steatohepatitis. | 2001 | Details |
| A28567 | 10804323 | Diabetes Metab | Non-alcoholic steatohepatitis: association with obesity and insulin resistance, and influence of weight loss. | 2000 | Details |
| A28570 | 10422091 | Nutrition | Nutritional and metabolic effects of alcoholism: their relationship with alcoholic liver disease. | 1999 | Details |
| A28645 | 35192632 | PLoS One | Ipragliflozin attenuates non-alcoholic steatohepatitis development in an animal model. | 2022 | Details |
| A28704 | 35113139 | Diabetes Care | Impaired Hepatic Mitochondrial Capacity in Nonalcoholic Steatohepatitis Associated With Type 2 Diabetes. | 2022 | Details |
| A28715 | 35102596 | Hepatology | Discovery of a INSIG binding compound that ameliorates nonalcoholic steatohepatitis by inhibiting SREBP-mediated lipogenesis. | 2022 | Details |
| A28733 | 35085894 | Biochem Biophys Res Commun | Liver cyclophilin D deficiency inhibits the progression of early NASH by ameliorating steatosis and inflammation. | 2022 | Details |
| A28740 | 35076966 | Hepatology | Persistence of severe liver fibrosis despite substantial weight loss with bariatric surgery. | 2022 | Details |
| A28763 | 35039610 | Lab Invest | High-fat diet-induced nonalcoholic steatohepatitis is accelerated by low carnitine and impaired glucose tolerance in novel murine models. | 2022 | Details |
| A28774 | 35024320 | Acta Pharm Sin B | A small molecule UPR modulator for diabetes identified by high throughput screening. | 2021 | Details |
| A28801 | 34986326 | Cell Chem Biol | An antisense transcript transcribed from Irs2 locus contributes to the pathogenesis of hepatic steatosis in insulin resistance. | 2022 | Details |
| A28817 | 34944770 | Biomedicines | Butyrate Protects against Diet-Induced NASH and Liver Fibrosis and Suppresses Specific Non-Canonical TGF-β Signaling Pathways in Human Hepatic Stellate Cells. | 2021 | Details |
| A28895 | 34855620 | J Clin Invest | Dyrk1b promotes hepatic lipogenesis by bypassing canonical insulin signaling and directly activating mTORC2 in mice. | 2022 | Details |
| A28928 | 34805145 | Front Cell Dev Biol | A Comparative Proteomic Analysis of Extracellular Vesicles Associated With Lipotoxicity. | 2021 | Details |
| A28936 | 34797360 | Food Funct | Effects of Salvia hispanica L. (chia) seed on blood coagulation, endothelial dysfunction and liver fibrosis in an experimental model of Metabolic Syndrome. | 2021 | Details |
| A29044 | 34659107 | Front Endocrinol (Lausanne) | NDUFB6 Polymorphism Is Associated With Physical Activity-Mediated Metabolic Changes in Type 2 Diabetes. | 2021 | Details |
| A29068 | 34626851 | Mol Metab | GLP-1 physiology informs the pharmacotherapy of obesity. | 2021 | Details |
| A29226 | 34390210 | FEBS Open Bio | Nonobese mice with nonalcoholic steatohepatitis fed on a choline-deficient, l-amino acid-defined, high-fat diet exhibit alterations in signaling pathways. | 2021 | Details |
| A29246 | 34363605 | J Physiol Biochem | HGF can reduce accumulation of inflammation and regulate glucose homeostasis in T2D mice. | 2021 | Details |
| A29345 | 34221233 | Oxid Med Cell Longev | Protein Phosphatase 4 Promotes Hepatocyte Lipoapoptosis by Regulating RAC1/MLK3/JNK Pathway. | 2021 | Details |
| A29435 | 34073868 | Cancers (Basel) | Mitochondrial Dynamics and Liver Cancer. | 2021 | Details |
| A29546 | 33903842 | Cureus | Clinical Management of Nonalcoholic Steatohepatitis (NASH) With the Use of Thiazolidinediones and the Additive Effect of Thiazolidinediones and a GLP-1 Agonist: Case Series. | 2021 | Details |
| A29609 | 33802238 | Cancers (Basel) | Cache Domain Containing 1 Is a Novel Marker of Non-Alcoholic Steatohepatitis-Associated Hepatocarcinogenesis. | 2021 | Details |
| A29611 | 33800470 | Biomedicines | C-Peptide as a Therapy for Type 1 Diabetes Mellitus. | 2021 | Details |
| A29736 | 33604255 | J Clin Transl Hepatol | New Drugs on the Block-Emerging Treatments for Nonalcoholic Steatohepatitis. | 2020 | Details |
| A29753 | 33564498 | Cureus | A Review of Pirfenidone as an Anti-Fibrotic in Idiopathic Pulmonary Fibrosis and Its Probable Role in Other Diseases. | 2021 | Details |
| A29792 | 33513920 | Biomedicines | Magnesium, Little Known But Possibly Relevant: A Link between NASH and Related Comorbidities. | 2021 | Details |
| A29876 | 33354276 | Oxid Med Cell Longev | Honokiol Alleviates Methionine-Choline Deficient Diet-Induced Hepatic Steatosis and Oxidative Stress in C57BL/6 Mice by Regulating CFLAR-JNK Pathway. | 2020 | Details |
| A29879 | 33344141 | Adv Sci (Weinh) | Triantennary GalNAc Molecular Imaging Probes for Monitoring Hepatocyte Function in a Rat Model of Nonalcoholic Steatohepatitis. | 2020 | Details |
| A29919 | 33277568 | Sci Rep | Discovery of a novel fibroblast activation protein (FAP) inhibitor, BR103354, with anti-diabetic and anti-steatotic effects. | 2020 | Details |
| A29942 | 33234375 | Environ Pollut | Transgenerational metabolic disorders and reproduction defects induced by benzo[a]pyrene in Xenopus tropicalis. | 2020 | Details |
| A29948 | 33212150 | Life Sci | Long-term co-administration of sodium nitrite and sodium hydrosulfide inhibits hepatic gluconeogenesis in male type 2 diabetic rats: Role of PI3K-Akt-eNOS pathway. | 2020 | Details |
| A30042 | 33073195 | ACS Pharmacol Transl Sci | Optimization of Peptide Inhibitors of β-Klotho as Antagonists of Fibroblast Growth Factors 19 and 21. | 2020 | Details |
| A30134 | 32923834 | Hepatol Commun | The Selective Peroxisome Proliferator-Activated Receptor Gamma Modulator CHS-131 Improves Liver Histopathology and Metabolism in a Mouse Model of Obesity and Nonalcoholic Steatohepatitis. | 2020 | Details |
| A30204 | 32821335 | World J Hepatol | Anti-inflammatory and anti-oxidant effects of aloe vera in rats with non-alcoholic steatohepatitis. | 2020 | Details |
| A30237 | 32764725 | Nat Rev Endocrinol | The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic. | 2020 | Details |
| A30277 | 32712104 | Gastroenterology | FXR Isoforms Control Different Metabolic Functions in Liver Cells via Binding to Specific DNA Motifs. | 2020 | Details |
| A30290 | 32694748 | Spinal Cord | A tele-health intervention to increase physical fitness in people with spinal cord injury and cardiometabolic disease or risk factors: a pilot randomized controlled trial. | 2020 | Details |
| A30300 | 32682196 | Eur J Med Chem | A novel long-acting oxyntomodulin analogue eliminates diabetes and obesity in mice. | 2020 | Details |
| A30395 | 32508961 | Nutr Metab (Lond) | High-trans fatty acid and high-sugar diets can cause mice with non-alcoholic steatohepatitis with liver fibrosis and potential pathogenesis. | 2020 | Details |
| A30480 | 32377219 | Nutr Metab (Lond) | Gypenosides regulate farnesoid X receptor-mediated bile acid and lipid metabolism in a mouse model of non-alcoholic steatohepatitis. | 2020 | Details |
| A30489 | 32355675 | Hepatobiliary Surg Nutr | Probiotics VSL#3 are effective in reversing non-alcoholic steatohepatitis in a mouse model. | 2020 | Details |
| A30564 | 32205234 | Pharmacol Res | Obesity and NRF2-mediated cytoprotection: Where is the missing link? | 2020 | Details |
| A30599 | 32140659 | Hepatol Commun | Pirfenidone Is an Agonistic Ligand for PPARα and Improves NASH by Activation of SIRT1/LKB1/pAMPK. | 2020 | Details |
| A30617 | 32099031 | Sci Rep | Inhibition of Grb14, a negative modulator of insulin signaling, improves glucose homeostasis without causing cardiac dysfunction. | 2020 | Details |
| A30665 | 32025605 | Hepatol Commun | Icosabutate Exerts Beneficial Effects Upon Insulin Sensitivity, Hepatic Inflammation, Lipotoxicity, and Fibrosis in Mice. | 2019 | Details |
| A30777 | 31798462 | Front Physiol | Characterising an Alternative Murine Model of Diabetic Cardiomyopathy. | 2019 | Details |
| A30810 | 31747961 | Stem Cell Res Ther | Treatment with adipose tissue-derived mesenchymal stem cells exerts anti-diabetic effects, improves long-term complications, and attenuates inflammation in type 2 diabetic rats. | 2019 | Details |
| A30825 | 31717307 | Cancers (Basel) | The mRNA-binding Protein TTP/ZFP36 in Hepatocarcinogenesis and Hepatocellular Carcinoma. | 2019 | Details |
| A30847 | 31680767 | Korean J Physiol Pharmacol | Efficacy of evogliptin and cenicriviroc against nonalcoholic steatohepatitis in mice: a comparative study. | 2019 | Details |
| A30956 | 31479766 | Nitric Oxide | Hydrogen sulfide potentiates the favorable metabolic effects of inorganic nitrite in type 2 diabetic rats. | 2019 | Details |
| A31019 | 31388629 | Hepatol Commun | Tropifexor-Mediated Abrogation of Steatohepatitis and Fibrosis Is Associated With the Antioxidative Gene Expression Profile in Rodents. | 2019 | Details |
| A31047 | 31321239 | Biomed Res Int | Elafibranor Inhibits Chronic Kidney Disease Progression in NASH Mice. | 2019 | Details |
| A31059 | 31294056 | Data Brief | Transcriptomics data of a human in vitro model of non-alcoholic steatohepatitis exposed to elafibranor. | 2019 | Details |
| A31100 | 31227742 | Sci Rep | Combined obeticholic acid and elafibranor treatment promotes additive liver histological improvements in a diet-induced ob/ob mouse model of biopsy-confirmed NASH. | 2019 | Details |
| A31229 | 31001415 | F1000Res | Recent advances in managing/understanding the metabolic syndrome. | 2019 | Details |
| A31276 | 30909602 | Cells | 2,4 Dinitrophenol as Medicine. | 2019 | Details |
| A31304 | 30846912 | Gastroenterol Hepatol (N Y) | Pharmacologic Management of Nonalcoholic Steatohepatitis. | 2018 | Details |
| A31310 | 30826467 | Biochim Biophys Acta Mol Basis Dis | Reduced biliverdin reductase-A levels are associated with early alterations of insulin signaling in obesity. | 2019 | Details |
| A31375 | 30705600 | Diabetes Metab Syndr Obes | Effects of duodenal-jejunal bypass surgery in ameliorating nonalcoholic steatohepatitis in diet-induced obese rats. | 2019 | Details |
| A31407 | 30631398 | World J Hepatol | Non-invasive prediction of non-alcoholic steatohepatitis in Japanese patients with morbid obesity by artificial intelligence using rule extraction technology. | 2018 | Details |